Dofequidar fumarate

CAS No. 153653-30-6

Dofequidar fumarate ( MS-209 )

Catalog No. M12171 CAS No. 153653-30-6

A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 41 Get Quote
5MG 69 Get Quote
10MG 114 Get Quote
25MG 232 Get Quote
50MG 447 Get Quote
100MG 651 Get Quote
500MG 1368 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Dofequidar fumarate
  • Note
    Research use only, not for human use.
  • Brief Description
    A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR.
  • Description
    A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR; completely reverses resistance against vincristine in vitro in multidrug-resistant variants of mouse leukemia P388 cells and human leukemia K562 cells at 1-10 uM; greatly reduces the SP-derived tumor growth in vivo combined with CPT-11.Breast cancer Phase 2 Discontinued
  • Synonyms
    MS-209
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    P-glycoprotein
  • Recptor
    P-glycoprotein
  • Research Area
    Cancer
  • Indication
    Breast Cancer

Chemical Information

  • CAS Number
    153653-30-6
  • Formula Weight
    597.66
  • Molecular Formula
    C34H35N3O7
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 56 mg/mL
  • SMILES
    C1CN(CCN1CC(COC2=CC=CC3=C2C=CC=N3)O)C(=O)C(C4=CC=CC=C4)C5=CC=CC=C5.C(=CC(=O)O)C(=O)O
  • Chemical Name
    Ethanone, 1-[4-[2-hydroxy-3-(5-quinolinyloxy)propyl]-1-piperazinyl]-2,2-diphenyl-, (2E)-2-butenedioate (1:1)

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Nakanishi O, et al. Oncol Res. 1997;9(2):61-9.
2. Sato W, et al. Cancer Chemother Pharmacol. 1995;35(4):271-7.
3. Katayama R, et al. Cancer Sci. 2009 Nov;100(11):2060-8.
molnova catalog
related products
  • Elacridar

    A potent inhibitor of multidrug resistance (MDR) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC50 of 0.02 uM.

  • Tariquidar methanesu...

    A potent, specific P-gp inhibitor with Kd of 5.1 nM.

  • Dofequidar

    A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR.